Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study - Sulkowski, Mark S.; Fessel, Walford J.; Lazzarin, Adriano; Berenguer, Juan; Zakharova, Natalia; Cheinquer, Hugo; Côté, Pierre; Dieterich, Douglas; Gadano, Adrian; Matthews, Gail; Molina, Jean-Michel; Moreno, Christophe; et al. (Hepatology international, 2017)
Keywords: Adult; Aged; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; Coinfection - drug therapy; Coinfection - virology; Colorectal Surgery; Drug Therapy, Combination; Female; Hepacivirus - drug effects; Hepacivirus - genetics; Hepatitis C virus; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Hepatology; HIV Infections - complications; HIV Infections - drug therapy; Humans; Imidazoles - administration & dosage; Imidazoles - adverse effects; Imidazoles - therapeutic use; Interferon-alpha - administration & dosage; Interferon-alpha - adverse effects; Interferon-alpha - therapeutic use; Lentivirus; Male; Medicine; Medicine & Public Health; Middle Aged; Original Article; Polyethylene Glycols - administration & dosage; Polyethylene Glycols - adverse effects; Polyethylene Glycols - therapeutic use; Recombinant Proteins - administration & dosage; Recombinant Proteins - adverse effects; Recombinant Proteins - therapeutic use; Retroviridae; Ribavirin - administration & dosage; Ribavirin - therapeutic use; Surgery; Treatment Outcome; Young Adult; Daclatasvir; HIV/HCV coinfection; Peginterferon alfa-2a/ribavirin; HCV GT-1